Direkte orale Antikoagulanzien bei Krebspatienten: Sind wir so weit?

Svetlana Sarinayova; Marc Heizmann

doi:10.1024/1661-8157/a002881

Direkte orale Antikoagulanzien bei Krebspatienten: Sind wir so weit?

Praxis (Bern 1994). 2018 Jan;107(3):145-151. doi: 10.1024/1661-8157/a002881.

[Article in German]

Authors

Svetlana Sarinayova¹, Marc Heizmann¹

Affiliation

¹ 1 Kantonsspital Aarau, Medizinische Universitätsklinik, Abteilungen für Onkologie, Hämatologie und Transfusionsmedizin.

PMID: 29382262
DOI: 10.1024/1661-8157/a002881

No abstract available

Keywords: Anticoagulants oraux directs; Direct oral anticoagulants; Direkte orale Antikoagulanzien; HBPM; Krebserkrankung; LMWH; Lungenembolie; NMH; Thrombose; cancer; embolie pulmonaire; pulmonary embolism; thrombose; thrombosis.

Publication types

Comparative Study
Review

MeSH terms

Administration, Oral
Anticoagulants / adverse effects
Anticoagulants / therapeutic use*
Antithrombins / adverse effects
Antithrombins / therapeutic use*
Drug Interactions
Factor Xa Inhibitors / adverse effects
Factor Xa Inhibitors / therapeutic use
Heparin, Low-Molecular-Weight / adverse effects
Heparin, Low-Molecular-Weight / therapeutic use
Humans
Neoplasms / blood*
Neoplasms / complications*
Neoplastic Cells, Circulating / drug effects*
Prospective Studies
Pulmonary Embolism / blood*
Pulmonary Embolism / drug therapy*
Treatment Outcome
Venous Thrombosis / blood
Venous Thrombosis / drug therapy*
Vitamin K / antagonists & inhibitors

Substances

Anticoagulants
Antithrombins
Factor Xa Inhibitors
Heparin, Low-Molecular-Weight
Vitamin K